Currently, although there are many emerging therapies for HER2-positive breast cancer, including TKIs, ADCs, and bispecific antibodies, trastuzumab is still irreplaceable in the treatment of HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.